Healthcare · Biotechnology
Price
$42.76
Market Cap
$2.5B
Employees
486
Beta
0.54
Avg Volume
1,134,312
CEO
Brian Goff
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Runs with full report
Price Overview
Last updated: Jul 8, 2026 7:18pm (just now)
Current data · timestamped when a report runs
$42.76
Change · Jul 8
-1.25 (-2.84%)
Day Range
$42.53 – $44.00
52-Week Range
$22.24 – $46.00
50-Day MA
$30.42
200-Day MA
$31.78
Volume
1,581,157.00
Analyst Price Targets
Low
$32.00
Consensus
$42.33
High
$54.00
(24 analysts)
Share Structure
Outstanding
59,471,600.00
Float
55,684,448.00
Free Float
93.6%
High free float
— 93.6% of shares trade freely, ~6.4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-6.01
Stock Price: $42.76
EPS (Diluted): -7.12
EPS (Diluted): -7.12
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.32
Stock Price: $42.76
Total Equity: $1.19B
Shares: 57,972,004
Total Equity: $1.19B
Shares: 57,972,004
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-5.89
Market Cap: $2.54B
Total Debt: $40.21M
Cash: $89.13M
EBITDA: -$408.62M
Total Debt: $40.21M
Cash: $89.13M
EBITDA: -$408.62M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$1.6B
Market Cap: $2.54B
Total Debt: $40.21M
Cash: $89.13M
Total Debt: $40.21M
Cash: $89.13M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
29.21
Stock Price: $42.76
Revenue: $54.03M
Shares: 57,972,004
Revenue: $54.03M
Shares: 57,972,004
EV/Sales (Total value vs revenue — works when P/E can't)
API28.71
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
78.7%
Gross Profit: $42.51M
Revenue: $54.03M
Revenue: $54.03M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-873.9%
Operating Income: -$472.13M
Revenue: $54.03M
Revenue: $54.03M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-764.0%
Net Income: -$412.78M
Revenue: $54.03M
Revenue: $54.03M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-34.1%
Net Income: -$412.78M
Total Equity: $1.19B
Total Equity: $1.19B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-41.4%
Operating Income: -$472.13M
Tax Rate: 0.2%
Equity: $1.19B
Total Debt: $40.21M
Cash: $89.13M
Tax Rate: 0.2%
Equity: $1.19B
Total Debt: $40.21M
Cash: $89.13M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
11.46
Current Assets: $942.05M
Current Liabilities: $82.21M
Current Liabilities: $82.21M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.03
Short-Term Debt: $18.39M
Long-Term Debt: $21.82M
Total Debt: $40.21M
Total Equity: $1.19B
Long-Term Debt: $21.82M
Total Debt: $40.21M
Total Equity: $1.19B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.93
Revenue: $54.03M
Shares: 57,972,004
Shares: 57,972,004
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$20.58
Total Equity: $1.19B
Shares: 57,972,004
Shares: 57,972,004
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-6.51
Operating CF: -$372.98M
CapEx: -$4.32M
Shares: 57,972,004
CapEx: -$4.32M
Shares: 57,972,004
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $42.76
Stock Price: $42.76
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$412.78M
Net Income: -$412.78M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AGIO against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $14.2M | $26.8M | $36.5M | $54.0M |
| Cost of Revenue | $18.8M | $1.7M | $9.5M | $4.2M | $11.5M |
| Gross Profit | -$18.8M | $12.5M | $17.3M | $32.3M | $42.5M |
| Operating Expenses | $359.6M | $401.6M | $408.8M | $458.1M | $514.6M |
| Operating Income | -$378.4M | -$389.0M | -$391.5M | -$425.7M | -$472.1M |
| Net Income | $1.6B | -$231.8M | -$352.1M | $673.7M | -$412.8M |
| EBITDA | -$337.7M | -$223.2M | -$345.5M | $723.6M | -$408.6M |
| EPS | $-6.36 | $-4.23 | $-6.33 | $11.86 | $-7.12 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $203.1M | $139.3M | $88.2M | $76.2M | $89.1M |
| Total Current Assets | $1.1B | $832.8M | $833.8M | $965.6M | $942.1M |
| Total Assets | $1.4B | $1.2B | $937.1M | $1.7B | $1.3B |
| Current Liabilities | $59.8M | $62.6M | $68.0M | $81.2M | $82.2M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $21.8M |
| Total Liabilities | $145.8M | $137.9M | $126.1M | $122.2M | $104.1M |
| Total Equity | $1.3B | $1.1B | $811.0M | $1.5B | $1.2B |
| Retained Earnings | -$238.8M | -$470.6M | -$822.6M | -$148.9M | -$561.7M |
Cash Flow (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$407.3M | -$309.5M | -$296.1M | -$389.8M | -$373.0M |
| Capital Expenditure | -$5.7M | -$4.9M | $-999,000 | -$1.7M | -$4.3M |
| Free Cash Flow | -$413.1M | -$314.4M | -$297.1M | -$391.5M | -$377.3M |
| Acquisitions (net) | $0 | $132.7M | $0 | $40,000 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$802.5M | $0 | $0 | $0 | $0 |
| Net Change in Cash | $75.7M | -$63.9M | -$51.1M | -$12.0M | $12.9M |
Analyst Estimates (Annual)
Last updated: Jul 8, 2026 7:18pm (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$256.8M $203.7M – $302.6M
|
$392.3M $392.3M – $392.3M
|
$530.9M $366.1M – $681.6M
|
$693.7M $478.4M – $890.7M
|
| EBITDA |
-$51.4M -$60.5M – -$40.7M
|
-$78.5M -$78.5M – -$78.5M
|
-$106.2M -$136.3M – -$73.2M
|
-$138.7M -$178.1M – -$95.7M
|
| Net Income |
-$293.0M -$332.8M – -$209.1M
|
-$212.8M -$276.5M – -$81.2M
|
-$110.5M -$151.2M – -$65.9M
|
-$10.0M -$13.7M – -$6.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | +88.4% | +36.1% | +48.0% |
| Gross Profit Growth | +166.8% | +38.2% | +86.7% | +31.5% |
| Operating Income Growth | -2.8% | -0.6% | -8.7% | -10.9% |
| Net Income Growth | -114.4% | -51.9% | +291.4% | -161.3% |
| EBITDA Growth | +33.9% | -54.8% | +309.5% | -156.5% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Gheuens Sarah | M-Exempt | 8,375.00 | $0.00 | $0 |
| 2026-07-01 | Gheuens Sarah | S-Sale | 4,007.00 | $37.56 | $150,503 |
| 2026-07-01 | Gheuens Sarah | M-Exempt | 8,375.00 | $0.00 | $0 |
| 2026-06-18 | Ballal Rahul D. | M-Exempt | 2,816.00 | $0.00 | $0 |
| 2026-06-18 | Ballal Rahul D. | A-Award | 14,950.00 | $34.16 | $510,692 |
| 2026-06-18 | Ballal Rahul D. | A-Award | 2,927.00 | $0.00 | $0 |
| 2026-06-18 | Ballal Rahul D. | M-Exempt | 2,816.00 | $0.00 | $0 |
| 2026-06-18 | CAPELLO JEFFREY D | A-Award | 14,950.00 | $34.16 | $510,692 |
| 2026-06-18 | CAPELLO JEFFREY D | M-Exempt | 2,816.00 | $0.00 | $0 |
| 2026-06-18 | CAPELLO JEFFREY D | A-Award | 2,927.00 | $0.00 | $0 |
| 2026-06-18 | CAPELLO JEFFREY D | M-Exempt | 2,816.00 | $0.00 | $0 |
| 2026-06-18 | Foster-Cheek Kaye I | A-Award | 14,950.00 | $34.16 | $510,692 |
| 2026-06-18 | Foster-Cheek Kaye I | M-Exempt | 2,816.00 | $0.00 | $0 |
| 2026-06-18 | Foster-Cheek Kaye I | A-Award | 2,927.00 | $0.00 | $0 |
| 2026-06-18 | Foster-Cheek Kaye I | M-Exempt | 2,816.00 | $0.00 | $0 |
| 2026-06-18 | FOUSE JACQUALYN A | M-Exempt | 2,816.00 | $0.00 | $0 |
| 2026-06-18 | FOUSE JACQUALYN A | A-Award | 14,950.00 | $34.16 | $510,692 |
| 2026-06-18 | FOUSE JACQUALYN A | A-Award | 2,927.00 | $0.00 | $0 |
| 2026-06-18 | FOUSE JACQUALYN A | M-Exempt | 2,816.00 | $0.00 | $0 |
| 2026-06-18 | Ho Maykin | M-Exempt | 2,816.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for AGIO — it's generated by the pipeline (
market-narrative step).
No community reviews yet for AGIO.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.392 · 5bda1781 · 2026-07-08 16:12:24